Pfizer Faces Patent Cliff As New Cancer Bets Grow

Pfizer ( (PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock.

Pfizer is deepening its oncology push while analysts remain cautiously optimistic about the stock. The company is collaborating with Astellas on the Phase 2 EV-209 trial, which combines enfortumab vedotin and pembrolizumab to treat muscle‑invasive bladder cancer without removing the bladder. If successful, the regimen could expand Pfizer’s role in urothelial cancer and support its long‑term oncology revenue story.

Wall Street sentiment on Pfizer stays mixed, with firms like Goldman Sachs and Scotiabank maintaining Buy ratings and price targets around $30–$33, implying a modest single‑digit upside from recent prices near $27. At the same time, many peers sit at Hold as investors weigh a looming $15–$20 billion patent cliff against a refreshed pipeline spanning early‑stage assets, new cancer trials, vaccines and obesity efforts.

Pfizer’s R&D engine is busy, with new first‑in‑human studies such as PF‑07328948 and expansion work in liver disease, pediatric ulcerative colitis and tafamidis aimed at diversifying future cash flows. In cancer, PF‑08634404 is being tested in advanced renal cell carcinoma, while management prunes weaker projects to focus spending on the most promising bets, signaling a more disciplined capital allocation approach.

For income‑oriented investors, Pfizer’s roughly 6% dividend helps cushion near‑term uncertainty as the company navigates generic competition for blockbusters like Ibrance, Eliquis and Xtandi. The stock is trading as a classic pipeline story: expectations for earnings growth are muted in the short run, but any major data readout—positive or negative—from its oncology or vaccine programs could quickly move PFE shares and reset market sentiment.